Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy

Journal of Theoretical Biology

Volumn 251, Issue 2, 2008, Pages 227-237

  Smith, Robert J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Dosing intervals; HIV therapy; Mathematical model; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

COMPARATIVE STUDY; DISEASE TREATMENT; DOSE-RESPONSE RELATIONSHIP; DRUG; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITION; INHIBITOR; NUMERICAL MODEL;

ARTICLE; DRUG DOSE REGIMEN; DRUG UPTAKE; HUMAN IMMUNODEFICIENCY VIRUS; MATHEMATICAL MODEL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS LOAD;

EID: 39749137464     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2007.11.032     Document Type: Article

References (26)

1. Calloway D.S., and Perelson A.S. HIV-1 infection and low steady state viral loads. Bull. Math. Biol. 64 (2002) 29-64
2. Calmy A., Petoumenos K., Lewden C., Law M., Bocquentin F., Hesse K., Cooper D., Carr A., and Bonnet F. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. HIV Med. 8 (2007) 171-180
3. Carpenter C. Universal access to antiretroviral therapy: when, not if. Clin. Infect. Dis. 42 (2006) 260-261
4. Department of Health and Human Services, 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 〈http://img.thebody.com/hivatis/pdfs/adult_guide.pdf〉 (accessed December 26, 2007).
5. Ghani A.C., Henley W.E., Donnelly C.A., Mayer S., and Anderson R.M. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 15 9 (2001) 1133-1142
6. Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R.A., Melroe H., Cavert W., Gebhard K., Staskus K., Zhang Z.Q., Dailey P.J., Balfour H.H., Erice A., and Perelson A.S. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274 (1996) 985-989
7. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 6510 (1995) 123-126
8. Huang Y., Rosenkranz S.L., and Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math. Biosci. 184 (2003) 165-186
9. Janeway C., Travers P., Walport M., and Shlomchik M.J. Immunobiology 5: The Immune System in Health and Disease (2001), Garland Publishing, New York
10. Krakovska O., and Wahl L.M. Costs versus benefits: best possible and best practical treatment regimens for HIV. J. Math. Biol. 54 3 (2007) 385-406
11. Moyle G. Protease inhibitor-sparing regimens: new evidence strengthens position. J. Acq. Immun. Def. Synd. 33 Suppl. 1 (2003) 17-25
12. Nelson P.W., and Perelson A.S. Mathematical analysis of delay differential equation models of HIV-1 infection. Math. Biosci. 171 1 (2002) 73-94
13. Nelson P.W., Murray J.D., and Perelson A.S. A model of HIV-1 pathogenesis that includes an intracellular delay. Math. Biosci. 163 (2000) 201-215
14. Nelson P.W., Mittler J.E., and Perelson A.S. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters. J. Acq. Immun. Def. Synd. 26 5 (2001) 405-412
15. Nowak M.A., and May R.M. Virus Dynamics (2000), Oxford University Press, Oxford
16. Perelson A.S. Modelling viral and immune system dynamics. Nature Reviews: Immunology 2 (2002) 28-36
17. Perelson A.S., and Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41 1 (1999) 3-44
18. Prior R.W. Looking around in awareness: playbuilding on HIV-AIDS. Res. Drama Educ. 10 1 (2005) 55-64
19. Raguin G., Chene G., Morand-Joubert L., et al. Puzzle 1 study group. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antiviral Ther. 9 (2004) 615-625
20. Schacker T.W., Hughes J.P., Shea T., Coombs R.W., and Corey L. Biological and virologic characteristics of primary HIV infection. Ann. Intern. Med. 128 8 (1998) 613-620
21. Smith R.J., and Wahl L.M. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 66 5 (2004) 1259-1283
22. Staszewski, S., Dauer, B., Von Hentig, N., et al., 2003a. The LOPSAQ study: 24 week analysis of the double protease inhibitor salvage regimen containing lopinavir plus saquinavir without any additional antiretroviral therapy. In: Second International AIDS Conference, Paris, France, July 2003 (Abstract 853).
23. Staszewski, S., Dauer, B., Gute, P., et al., 2003b. The CrixiLop cohort study: preliminary results from a salvage study of HIV positive patients treated with indinavir and lopinavir/ritonavir without the addition of reverse transcriptase inhibitors. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 2003 (Abstract H-853).
24. Wahl L.M., and Nowak M.A. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. London Ser. B 267 (2000) 835-843
25. Wu H., and Ding A. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55 2 (1999) 410-418 10.1111/j.0006-341X.1999.00410.x
26. Wu H., Huang Y., Acosta E.P., Park J.-G., Yu S., Rosenkranz S., Kuritzkes D.R., JEron J., Perelson A.S., and Gerber J.G. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J. Pharmacokinet. Pharmacodyn. 33 4 (2006) 399-419